Computerized systems and databases for pharmacovigilance in Russia
https://doi.org/10.37489/2782-3784-myrwd-60
EDN: KYAGES
Abstract
The results of identifying new risks for pharmacovigilance systems and databases in Russia, including the Roszdravnadzor's web-based pharmacovigilance system, are presented. The lack of information in the database on pharmacovigilance of the Eur asian Economic Union and problems with updating programs and using alternative systems were noted. Changes in RWD/RWE information in global pharmacovigilance over the past 5 years.
Objectives. Identification of new risks associated with pharmacovigilance systems and databases in Russia. Materials and methods. The materials were obtained by interviewing 138 pharmacovigilance specialists and from regula tory legal acts, publications, computerized systems, and databases through open and authorized access. Sociological methods were used: survey in Telegram-group «Pharmacovigilance CIS» in October 2024 and information-analytical methods: user testing, review, and analysis of Russian and foreign systems and programs, including databases for pharmacovigilance, regu latory documentation, and bibliography.
Results. 17 % of pharmacovigilance specialists use exclusively Russian software in their computerized systems and data bases, 29 % use only foreign software, 35 % use both Russian and foreign software, and 19 % find it difficult to classify their systems and programs as domestic or foreign. The results of user testing indicate that there are problems and risks with access ing Roszdravnadzor’s web-based pharmacovigilance system via foreign browsers in current versions of Windows, Android, MacOS, iOS, and Unix operating systems. The unified pharmacovigilance database of the Eurasian Economic Union as of No vember 5, 2024, contains no public access notifications. The composition of data in the global database, VigiBase, has changed over 5 years: the largest number of cases now relates to COVID-19 vaccines. Russian data were not included in EudraVigilance and VigiBase (from October 10, 2020), which does not allow them to be considered in the global analysis.
Conclusion. New potential risks for computerized systems and databases for pharmacovigilance in Russia have been iden tified — loss of data and reduction in the quality of analysis.
Keywords
About the Authors
B. K. RomanovRussian Federation
Boris K. Romanov — MD, associate professor, head of the Department of Pharmacology of the Institute of Pharmacy and Medical Chemistry
Moscow
Competing Interests:
The authors declare no conflict of interest
E. N. Saykina
Russian Federation
Ekaterina N. Saykina — postdoc of the Department of Pharmacology of the Institute of Pharmacy and Medical Chemistry
Moscow
Competing Interests:
The authors declare no conflict of interest
E. Yu. Baidikova
Russian Federation
Elizaveta Yu. Baidikova — 3rd year student of the Institute of Pharmacy and Medical Chemistry
Moscow
Competing Interests:
The authors declare no conflict of interest
U. M. Shirokova
Russian Federation
Ulyana M. Shirokova — 3rd year student of the Institute of Pharmacy and Medical Chemistry
Moscow
Competing Interests:
The authors declare no conflict of interest
E. D. Shchukin
Russian Federation
Egor D. Shchukin — 3rd year student of the Institute of Pharmacy and Medical Chemistry
Moscow
Competing Interests:
The authors declare no conflict of interest
References
1. Bo charnikov I.V. History of anti-Russian sanctions: from Ivan the Terrible to the present day.
2. Prohibition on Certain Information Technology and Software Services. Determination pursuant to section 1(a)(ii) of executive order 14071. URL: https://ofac.treasury.gov/media/932951/download?inline (дата обращения: 11.11.2024).
3. Telegram group "Pharmacovigilance CIS".
4. Goloenko N.G., Yagudina R.I., Ku likov A.Yu., Serpik V.G., Protsenko M.V., Kara petyan D.G. Results of a Sociological Survey on the Needs of Drug Safety Monitoring Specialists for Information on the Creation of the Pharma covigilance System Master File. Safety and Risk of Pharmacotherapy. 2020;8(2):84-89. (In Russ.).
5. Decision of the Council of the Eur asian Economic Commission of May 19, 2022 No. 81 "On Amendments to the Rules of Good Phar macovigilance Practice of the Eurasian Economic Union".
6. Order of Roszdravnadzor dated June 17, 2024 No. 3518 "On approval of the Procedure for pharmacovigilance of medicinal products for medical use."
7. Pharmacovigilance/ Monitoring of clinical trials of medicinal prod ucts. Electronic database of the Automated infor mation system of Roszdravnadzor.
8. Unified information data base of the Eurasian Economic Union on identified adverse reactions (actions) to medicinal products, including reports of medicinal product inefficien cy. Electronic database of the safety monitoring program. URL: http://www. eurasiancommission.org/ru/act/texnreg/deptexreg/LSMI/Pages/LS_database.aspx (дата обращения: 11.11.2024)
9. EudraVigilance – European database of suspected adverse drug reaction reports. Электронная база данных европейской программы мониторинга безопасности. URL: https://www.adrreports.eu/en/search_subst.html (дата обращения: 11.11.2024).
10. VigiAccess. Электронная база данных (открытый доступ) глобальной программы мониторинга безопасности. URL: https://vigiaccess.org (дата обращения: 11.11.2024).
11. VigiLyze. Электронная база данных (экспертный доступ) глобальной программы мониторинга безопасности. URL: https://vigilyze.whoumc.org (дата обращения: 11.11.2024).
12. Registry of Russian software URL: https://reestr.digital.gov.ru (дата обращения: 11.11.2024)
Review
For citations:
Romanov B.K., Saykina E.N., Baidikova E.Yu., Shirokova U.M., Shchukin E.D. Computerized systems and databases for pharmacovigilance in Russia. Real-World Data & Evidence. 2024;4(3):33-42. (In Russ.) https://doi.org/10.37489/2782-3784-myrwd-60. EDN: KYAGES